Bristol-Myers' HCV Drug Access Program Meets Criticism

Bristol-Myers Squibb Co (BMY) has been working on an access plan, called HCV Developing World Strategy, for its latest Hepatitis C drug Daklinza (daclatasvir). The plan may encompass tiered pricing to make the drug available to populations in low-to-mid income countries at more affordable prices, and is somewhat similar to steps taken by Gilead Sciences, Inc. (GILD).